

19 April 2024

ASX Announcement

OVARIAN CANCER TEST VALIDATION

INOVIQ Limited (ASX:IIQ or **INOVIQ**) is pleased to announce the successful completion of an analytical validation study for its blood test for ovarian cancer. Overall, the test correctly identified 85% of all samples tested (76% of the cancer samples and 94% of the cancer free samples).

The blood test is a simple, accurate and affordable combination immunoassay developed using both a CA125 monoclonal antibody (used by leading diagnostic companies) combined with our SubB2M detection reagent. The addition of SubB2M ensures that the test only detects CA125 that is produced by cancer cells, resulting in improved specificity for cancer and potentially a reduced number of false positive test results.

The SubB2M/CA125 test has been analytically validated to have:

- Excellent **reproducibility** with less than 5% variability within assays and less than 10% variability between assays;
- Acceptable **Limit of Quantitation** of less than 4 Units of CA125 per ml of serum;
- **High overall accuracy** in 334 sample study with sensitivity of 76% and specificity of 94% for detection of ovarian cancer; and
- **Equivalence** to a leading CA125 test for detection of ovarian cancer (see graph).




Figure 1. Receiver Operating Characteristic (ROC) curves for INOVIQ's (red) and Comparator CA125 (blue) tests. A ROC curve is a measure of the diagnostic performance of a test. The closer to the Reference line (black) the less accurate the test. The AUC summarises the overall performance of the test (1.0 = completely accurate, 0.5 = not useful). The data establish substantial equivalence of INOVIQ's SubB2M-CA125 with the comparator test.

Test	AUC ± SE	n
SubB2M/CA125	0.956 ± 0.010	334
Comparator- CA125	0.943 ± 0.012	334

CEO Leeearne Hinch said: "With analytical validation complete, we want to refine our test to see if we can further improve the test performance before moving to clinical validation."

Chairman David Williams said: "INOVIQ is seeking to demonstrate our SubB2M technology can be a superior detection reagent to improve the performance of multiple cancer biomarker tests. This will showcase the commercial potential of SubB2M for multiple cancers."

Authorised for release by the Company Secretary, Mark Edwards.

Further Information

Dr Leearne Hinch

Chief Executive Officer

E lhinch@inoviq.com

M +61 400 414 416

David Williams

Chairman

E dwilliams@kidder.com.au

M +61 414 383 593

ABOUT INOVIQ LTD

INOVIQ Ltd (ASX:IIQ) is a biotechnology company developing next-generation diagnostics and therapeutics for cancer. INOVIQ has commercialised its fast, efficient and scalable EXO-NET exosome isolation technology for biomarker discovery and diagnostics development, and the hTERT test as an adjunct test for bladder cancer. The company is advancing clinical-stage diagnostics for detection and monitoring of ovarian and breast cancers, and early-stage exosome therapeutics for solid tumours. For more information on INOVIQ, visit www.inoviq.com.